Table 4 Patients characteristics related to morality
Clinical features | Death group(n = 10) | Survival group | P value |
|---|---|---|---|
(n = 12) | |||
Male/Female(n) | 7(70.0%)/3(30.0%) | 8(80.0%)/4(40.0%) | 1.000 |
Age (years) | 53 ± 12.9(33~70) | 40 ± 14.7(25~70) | 0.050 |
Duration (weeks) | 19 ± 24.8(10~48) | 34 ± 69.2(0.83~216) | 0.547 |
Extrapulmonary manifestations (n) | |||
Fever | 3 (30.0%) | 7 (58.3%) | 0.231 |
Skin lesions (purpura, gangrene, ulceration) | 3 (30.0%) | 3 (25.0%) | 1.000 |
Ear (hearing loss, otitis media) | 2 (20.0%) | 4 (33.3%) | 0.646 |
Nasal and sinus involvement | 5 (50.0%) | 7 (58.3%) | 1.000 |
Oral ulceration | 4 (40.0%) | 1 (8.3%) | 0.135 |
glomerulonephritis | 6 (60.0%) | 6 (50.0%) | 0.691 |
Nervous system (facial paralysis, multiple mononeuropathy, etc.) | 3 (30.0%) | 1 (8.3%) | 0.293 |
Arthralgia/arthritis | 4 (40.0%) | 4 (33.3%) | 1.000 |
Parotid swelling and pain | 2 (20.0%) | 0 (0.0%) | 0.195 |
ESR(mm/h) | 104 ± 26.7 | 82 ± 33.9 | 0.233 |
Infection(n) | 6 (60.0%) | 3 (25.0%) | 0.192 |
Corticosteroids and Immunosuppressants (n) | |||
steroid pulse therapy | 1 (10.0%) | 4 (33.3%) | 0.323 |
treatment interruption | 2/4(50.0%) | 0/8(0.0%) | 0.091 |
Non-response to Pleural drainage (n) | 5/5 (100%) | 0/7 (0.0%) | 0.010 |
Surgery(n) | 2 (20.0%) | 5 (41.7%) | 0.381 |